Sensus Healthcare (SRTS) Q2 2026 earnings review
Revenue Collapses While Tax Write-Off Contradicts Profitability Promises
Sensus Healthcare reported a disastrous second quarter, with revenue decelerating 68% YoY to a mere $2.3M and net loss swelling to $8.7M. Management attributes the shortfall to the delayed financing of eight systems (shifting revenue to Q3) and the deliberate pivot away from a historically large customer. However, the underlying unit economics tell a tougher story: even adding the 8 delayed units back to the 11 recognized would only match last year's 19 units, while the heavy mix shift toward recurring revenue (Fair Deal Agreements) and lower-priced international sales is crushing gross margins. The most glaring red flag is a $5.7M valuation allowance against deferred tax assets—a move that fundamentally undermines management's previous guidance of reaching full-year profitability in 2026.
🐂 Bull Case
Eight purchased units were pushed to Q3 strictly due to financing approval timing. Recognizing these units will provide an immediate sequential revenue rebound.
On top of the January 1 implementation of dedicated CPT codes, CMS has now proposed a 26% increase in the hospital-based SRT delivery code, significantly improving provider economics.
🐻 Bear Case
The company booked a $5.7M valuation allowance against net deferred tax assets. Auditors require this when it is 'more likely than not' the company won't generate enough near-term taxable income to utilize them—directly contradicting management's prior '2026 profitability' narrative.
The transition away from upfront capital sales to Fair Deal Agreements (FDA) and rentals is devastating current-period revenue and margins. Gross margin sits at a depressed 34.8%.
⚖️ Verdict: 🔴
Bearish. Management claims the pipeline is strong, but actual recognized revenue is vanishing. The combination of accelerating cash burn and the deferred tax valuation allowance suggests the internal outlook is much darker than the external narrative.
Key Themes
Valuation Allowance Undermines Profitability Goal
In prior quarters, CEO Joe Sardano set an explicit objective to 'achieve full-year profitability in 2026'. In Q2, the company recorded a $5.7M valuation allowance against net deferred tax assets. This accounting treatment is typically mandatory when management and auditors conclude that future taxable income is highly unlikely to be sufficient to realize those assets. This specific data point severely damages the credibility of the company's near-term profitability timeline.
The Revenue vs. Volume Disconnect
Management blamed the $5.0M revenue shortfall on eight delayed units. However, basic math reveals a deeper structural issue. Q2 recognized 11 units. Adding the 8 delayed units equals 19 units total—exactly flat YoY with 25Q2's 19 units. Yet, even if all 19 were recognized, revenue would likely still be significantly lower YoY. This confirms that the mix shift toward Fair Deal Agreements (revenue recognized over time) and international markets (lower ASPs) is structurally resetting the company's revenue baseline downward.
CMS Hospital Code Boost
A newly proposed 26% increase in the hospital-based SRT delivery code by CMS serves as a major macro tailwind. If finalized, this adds to the dedicated CPT codes implemented on January 1, further expanding the economic incentive for adoption not just in independent dermatology practices, but across larger health systems and hospital settings.
International Expansion Masks Domestic Weakness
International activity remains a focal point, expanding across the Asia-Pacific region, specifically Australia and New Zealand. While this broadens the total addressable market and replaces volume lost from the legacy U.S. mega-customer, these shipments carry lower average selling prices. This geographic mix shift was cited as a primary reason gross margins decelerated YoY from 39.7% to 34.8%.
Digital/Software Recurring Revenue Shift
The company continues its operational pivot from hardware to recurring revenue, leveraging its proprietary Sensus Link software and Sentinel platforms. By aligning with the new weekly physics consult codes, Sensus is attempting to build a high-margin revenue share model. However, the execution lag is painful, as upfront capital sales vanish faster than recurring revenue can fill the void.
Other KPIs
Accelerating burn. Cash balances fell steeply from $18.3M at the end of Q1 2026 to $15.2M in Q2. While the company maintains zero debt, a $3.1M quarterly cash burn rate significantly shortens the runway if the promised second-half revenue rebound fails to materialize.
Decelerating. Total operating expenses dropped from $4.8M in 25Q2 to $3.9M in 26Q2. Management is demonstrating tight cost control across G&A, S&M, and R&D (R&D down 26.7% due to lower lobbying and development costs). This disciplined expense management is the only thing preventing operating losses from spiraling further.
Guidance
Accelerating. Management explicitly guided that revenue from the eight units delayed in Q2 due to financing approvals will be recognized in Q3. This guarantees a sequential unit volume bump.
Management stated they remain 'committed to delivering strong performance during the second half of 2026.' However, with the lack of quantitative guidance and the heavy deferred tax write-off, the market will likely heavily discount this commentary.
Key Questions
The Valuation Allowance Disconnect
You previously set an objective of reaching full-year profitability in 2026. How do you reconcile that goal with the auditor-mandated $5.7M valuation allowance against deferred tax assets this quarter?
Unit Mix and ASP Deterioration
If the 8 delayed units had closed in Q2, unit volume would have been perfectly flat YoY at 19 units. Given the shift toward Fair Deal Agreements and lower ASP international sales, what is your new normalized revenue expectation for a 19-unit quarter?
Domestic Pipeline Conversion
With the dedicated CPT codes active since January 1, the pipeline has allegedly been building. Beyond the 8 delayed units, why hasn't this translated into organic domestic growth ex-large customer, and when exactly will that inflection point occur?